ClinicalTrials.gg
Active, not recruitingNCT07216742GRACEUpdated Nov 5, 2026

Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.

A Phase 3 interventional study of hMG subcutaneous injection and Placebo in Infertility (IVF Patients), sponsored by Granata Bio Corporation. Active, not recruiting at 16 sites in United States. Open to female participants aged 18 Years to 42 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Granata Bio Corporation · Phase 3, Interventional, and Treatment

Updated Nov 5, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
659
Allocation
Randomized
Ages
18 Years to 42 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 395 studies in Infertility with a site in United States — 63 open to participants now, 85 under way, 7 of them phase 3. Infertility · United States.

Planned enrollment
22nd of 274
659 · median 89
Started
2025
with 20 others
Phase 3
26 of 395
3 open now
Primary completion
2028-11
later than 57 of 83 live
Registered
380th of 395
by date

Among the 395 studies in Infertility with a site in United States, this one is the 22nd largest by planned enrollment of the 274 interventional ones that give a count, is one of 21 that started in 2025, is one of 26 in phase 3, reaches primary completion later than 57 of the 83 other live ones, and was the 380th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

63 of the 395 studies in Infertility with a site in United States are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 42 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Infertility with a site in United States, or all of them as a file.
02

Study summary

The goal of this multicenter, randomized, placebo-controlled, double-blind clinical trial is toto evaluate the efficacy and safety of a human menopausal gonadotropin (hMG) in the development of multiple follicles, pregnancy, and cumulative live birth as part of an Assisted Reproductive Technology (ART) cycle in in women with a diagnosis of infertility.

03

Conditions studied

  • Infertility (IVF Patients)

Browse trials for

Keywords

  • Controlled ovarian stimulation
  • Gonadotropins
  • frozen embryo transfer
  • cumulative live birth rate
  • hMG
04

Who can participate

Ages eligible
18 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pre-menopausal women aged 18-42 years old at the time of consent.
  • ≥18 and \<38 kg/m² at the time of consent.
  • Menstrual cycles between 21-35 days.
  • Normal mammogram or breast ultrasound if patient is >40 or if participant is younger as indicated by physician recommendation, within 2 years of screening.
  • Anti-Müllerian hormone (AMH) >1.2 ng/ml within 6 months of screening.
  • If donor sperm is used, donor must be 18-40 years of age at the time of collection and compliant with 21 Code of Regulations (CFR) section 1271 Subpart C.
  • Transvaginal ultrasound (TVUS) documenting presence and adequate visualization of both ovaries without ovarian enlargement, normal adnexa, and both ovaries accessible for oocyte retrieval at screening or within 6 months of screening.
  • Valid medical indication for in vitro fertilization (IVF) treatment and subsequent embryo transfer (i.e. history of infertility according to current American Society of Reproductive Medicine (ASRM) definition, single women or same-sex couples) with the intention to achieve pregnancy within 12 months of the first stimulation cycle.
  • Hysterosalpingography, hysteroscopy or saline infusion sonography, documenting a normal uterine cavity (i.e. no müllerian duct anomaly, uterine fibroids, endometrial polyps, intrauterine adhesions, adenomyosis) at screening or within 1 year prior to screening.
  • Cervical cancer screening completed per current American College of Obstetricians and Gynecologists (ACOG) guidelines. Participants with abnormal findings may be included if deemed not and not a safety concern for mother or fetus, at the discretion of the PI
  • Negative serum surface antigen, antibody, (HIV) antibody tests at screening.
  • Absence of hydrosalpinx confirmed by hysterosalpingogram (HSG), sonohysterogram, laparoscopy, or other appropriate imaging within the past 12 months.
  • Willing to undergo up to two ovarian stimulation cycles prior to frozen embryo transfer.
  • Willing to self-administer study medications.
  • Willing to have trophectoderm of all blastocyst stage embryos.
  • Willing to accept transfer of one euploid embryo.
  • Willing to vitrify and warm embryo(s) with intention to have a Frozen Embryo Transfer (FET).
  • Willing and able to comply with the protocol and schedule of events for the duration of the study as well as providing delivery data and neonatal health data.

Exclusion criteria

Exclusion Criteria:

  • Persistent (for >1 cycle), (per PI discretion) ovarian cystic lesion (≥20 mm), including ovarian endometrioma or dermoid cyst.
  • Participants with hepatic impairment (liver function tests > 2x ). Participants with renal impairment (estimated \<60 mL/min/1.73 m2).
  • Uncontrolled adrenal, thyroid dysfunction or uncontrolled diabetes ( >7% within 3 months from screening).
  • Greater than one IVF cycle canceled due to inability to meet ovulation trigger criteria (i.e. at least 2-3 follicles reach ≥18 mm.).
  • History of recurrent implantation failure (RIF), defined according to the Lugano Consensus as the absence of implantation after transfer of ≥4 good-quality embryos in ≥3 embryo transfer (ET) cycles in women under the age of 40, using autologous oocytes.
  • Recurrent pregnancy loss (RPL) is defined by two or more miscarriages; that is clinical pregnancies with the same partner and documented by ultrasonography or histopathological examination.
  • Known history of anovulation.
  • Antral Follicle Count (AFC) \<5 at screening.
  • One or more dominant follicles (≥11 mm) observed on TVUS prior to randomization on stimulation day 1 with evidence of functional activity defined as serum Estradiol level >100 pg/ml.
  • Past or current history of an estrogen dependent
  • Untreated atypical endometrial hyperplasia
  • Any to the use of oral
  • History of OHSS.
  • Morphological sperm evidence of globozoospermia or prior failed oocyte fertilization in previous IVF cycle.
  • The use of donor sperm back up or rescue for fertilization of oocytes.
  • Use of calcium ionophore or treatment of sperm with methyl xanthines.
  • The need for surgically retrieved sperm (i.e. testicular sperm extraction [TESE], Percutaneous Epididymal Sperm Aspiration [PESA]).
  • Use of any drug throughout the study, or within 3 months before screening or 5 half-lives whichever is longer.
  • Use of any concomitant medications that would interfere with the study drug and with the evaluation of the study (e.g., hormonal medications or other medications affecting reproductive function), as determined by the investigator, unless permitted by the protocol or meeting required criteria.
  • Current use or dependence on psychotropic medications that are contraindicated during pregnancy or have known or suspected fetal risk, unless the Investigator determines that the potential benefit outweighs the risk.
  • Required chronic use of non-steroidal anti-inflammatory drugs during cycle.
  • Treatment with clomiphene citrate, metformin, cabergoline, gonadotropins, or GnRH analogs within 1 month prior to randomization.
  • Pregnancy, lactation, or contraindication to gonadotropins.
  • Known thrombophilia or history of blood clots unless fully evaluated and cleared by a hematologist and receiving appropriate prophylaxis.
  • Known abnormal karyotype in the patient or her partner that is considered clinically significant, such as numerical or structural chromosomal abnormalities (e.g., translocations, inversions, aneuploidies) known to impair fertility, increase risk of miscarriage, or result in genetic disorders in offspring.
  • Current tobacco or marijuana user.
  • Current or past (last 12 months) abuse of alcohol or drugs.
  • Current use of dietary supplements containing high dose of biotin (>300µg), if prior use washout period of 1 week prior to randomization.
  • No use of bioidentical hormones during stimulation or up to three months prior to start of stimulation. If prior use: washout period of three months prior to being randomized.
  • A history of chemotherapy or radiotherapy.
  • Undiagnosed uterine bleeding.
  • Tumors of the ovary, breast, adrenal gland, pituitary, or hypothalamus; malformation of sexual organs incompatible with pregnancy.
  • Known active pelvic inflammatory disease.
  • Current, untreated submucosal fibroids or Intramural fibroids ≥5 cm or otherwise clinically relevant pathology that could impair embryo implantation or pregnancy continuation.
  • The presence of severe endometriosis (ASRM stage 3 or stage 4) confirmed by laparoscopy, Magnetic Resonance Imaging (MRI), or pelvic ultrasound.
  • Concomitant participation in another study protocol.
  • Couples identified as carriers of the same autosomal recessive genetic condition associated with serious health outcomes in offspring will be excluded from the trial.
  • Planned use of a gestational carrier.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
659 participants (estimated)

Study arms

  • Experimental
    hMG

    Human Menopausal Gonadotropin, daily subcutaneous injection

    Drug: hMG subcutaneous injection

  • Placebo comparator
    Placebo

    Placebo, daily subcutaneous injection

    Drug: Placebo

Interventions

  • DrughMG subcutaneous injection

    daily subcutaneous injection

  • DrugPlacebo

    daily subcutaneous injection

06

What researchers measure

Primary outcomes

  1. cumulative live birth rate

    cumulative live birth rate following vitrified-thawed, single-euploid blastocyst transfer(s)

    Time frame: 12 months

Secondary outcomes

  1. Positive pregnancy (serum β-human chorionic gonadotropin [hCG])

    Time frame: 10 +/-2 days after Embryo transfer

  2. Clinical pregnancy (intrauterine gestational sac with fetal heartbeat)

    Time frame: 5 weeks ± 6 days post-embryo transfer

  3. Ongoing pregnancy (intrauterine pregnancy with fetal heartbeat)

    Time frame: 10 weeks ± 6 days post-embryo transfer (ET)

  4. Live birth rate

    Time frame: 9 months after ET

  5. Number of oocytes retrieved per stimulation cycle

    Time frame: 12-22 days after controlled ovarian stimulation start

  6. Number of metaphase II (MII) oocytes retrieved

    Time frame: 12-22 days after controlled ovarian stimulation start

  7. Fertilization rate (proportion of MII oocytes with normal fertilization)

    Time frame: 12-22 days after Controlled Ovarian stimulation start

  8. Number of Day 5 blastocysts from oocyte retrievals from Period 1 and Period 2

    Time frame: 12-22 days after controlled ovarian stimulation start

  9. Total gonadotropin dose required per stimulation cycle

    Time frame: 12-20 days after start Controlled ovarian stimulation

  10. Serum estradiol concentration on the day of ovulation trigger

    Time frame: 12-20 days after controlled ovarian stimulation start

  11. Serum progesterone (P4) on Day 5 of stimulation

    Time frame: 5 days after start controlled ovarian stimulation

  12. Serum Follicular Stimulation Hormone (FSH) level on stimulation day 1, pre-dose

    Time frame: 1 day of stimulation

  13. Serum Luteinizing hormone (LH) level on stimulation day 1, pre-dose

    Time frame: 1 day of stimulation

  14. Serum human Chorionic Gonadotropin (hCG) level on stimulation day 1, pre-dose

    Time frame: 1 day of stimulation

  15. FSH level on stimulation day 1, 1-4 hours post dose

    Time frame: 1 day of stimulation

  16. LH level on stimulation day 1, 1-4 hours post dose

    Time frame: 1 day of stimulation

  17. hCG level on stimulation day 1, 1-4 hours post dose

    Time frame: 1 day of stimulation

  18. FSH level on stimulation day 5

    Time frame: After 5 day of stimulation

  19. LH level on stimulation day 5

    Time frame: After 5 day of stimulation

  20. hCG level on stimulation day 5

    Time frame: After 5 day of stimulation

  21. FSH level on last stimulation day

    Time frame: 12-20 days after controlled ovarian stimulation start

  22. LH level on last stimulation day

    Time frame: 12-20 days after controlled ovarian stimulation start

  23. hCG level on last stimulation day

    Time frame: 12-20 days after controlled ovarian stimulation start

  24. FSH level on oocytes retrieval day

    Time frame: 12-22 days after controlled ovarian stimulation start

  25. LH level on oocytes retrieval day

    Time frame: 12-22 days after controlled ovarian stimulation start

  26. hCG level on oocytes retrieval day

    Time frame: 12-22 days after controlled ovarian stimulation start

Other outcomes

  1. Incidence, severity, timing, and duration of treatment-emergent adverse events (TEAEs), including action taken and outcome

    Time frame: up to 10 weeks post embryo transfer

  2. Injection sites reactions (e.g., pain, erythema, swelling)

    Time frame: 20 days after Controlled ovarian stimulation start

  3. Incidence of early and late ovarian hyperstimulation syndrome (OHSS)

    Time frame: up to 10 weeks post Embryo transfer

  4. Development of treatment-emergent anti-drug antibodies

    Time frame: up to 5 weeks +/- 6 days after embryo transfer

  5. Singleton live birth

    Time frame: 9 months post embryo transfer

  6. Multiple gestations (twins, triplets, or higher-order multifetal pregnancies)

    Time frame: 9 months after Embryo transfer

  7. Biochemical pregnancy loss

    Time frame: up to 6 weeks after embryo transfer

  8. Ectopic pregnancy

    Time frame: Up to 6 weeks after embryo transfer

  9. Early pregnancy loss

    Time frame: Up to 12 weeks of gestation

  10. Intrauterine fetal demise

    Time frame: up to 9 months after embryo transfer

  11. Incidence of maternal/pregnancy complications

    Time frame: up to 9 months after embryo transfer

  12. Preterm birth

    Time frame: up to 37 weeks of gestation

  13. Small for gestational age

    Time frame: up to 9 months after Embryo transfer

  14. Stillbirth

    Time frame: up to 9 months after embryo transfer

07

Study locations

16 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2028, 36 months after the start.

Of 25 industry-sponsored phase 3 interventional studies under Infertility, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 36 months is above that.

Counting every sponsor, half of 59 studies reached it within 24 months; a quarter within 16 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Oct 15, 2025
StartActual
Nov 1, 2025
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07216742
Lead sponsor
Granata Bio Corporation
Responsible party
Sponsor
First posted
Oct 15, 2025
Start date
Nov 1, 2025
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion